Risk factors
Sanara MedTech (SMTI) risk factors
Item 1A of every Sanara MedTech Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
35 risks, 3 dropped, 6 reworded since the prior year. Sanara MedTech dropped risks concerning its value-based wound strategy and expanded market entry. Patent protection details for CellerateRX Surgical were updated. Regulatory and R&D disclosures were revised.
Filed Mar 24, 2026 - FY2024 10-K risk factors
38 risks. SMTI faces significant risks from ongoing financial losses, heavy reliance on non-patented CellerateRX Surgical, and strict debt covenants.
Filed Mar 25, 2025